Announcing the launch of Breakthroughs Today, Cures Tomorrow, our 20th anniversary campaign!
$40M
Million in NET research funding
50
Active Research
Projects
17
Countries with ongoing studies
The early results from a first-in-human clinical trial suggest that a novel copper-based PET imaging
Chimeric Therapeutics has reported that a neuroendocrine cancer patient in the Phase 1 clinical trial
By Anna Greene, PhD, NETRF Chief Scientific Officer NETRF-funded scientists uncover how oxygen levels shape
You can support a brighter future. Make a gift. Host an event. Or volunteer to help us advance our understanding of neuroendocrine tumors.
Learn about neuroendocrine tumor tests, treatments, and research. Find out about educational and inspirational events in the NET community.
NETRF hosts free patient and caregiver neuroendocrine tumor conferences to educate and empower individuals to be part of their care planning and live their best life.
